Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Tim Rolph"'
Autor:
Erik J. Tillman, Tim Rolph
Publikováno v:
Frontiers in Endocrinology, Vol 11 (2020)
The rising global prevalence of obesity, metabolic syndrome, and type 2 diabetes has driven a sharp increase in non-alcoholic fatty liver disease (NAFLD), characterized by excessive fat accumulation in the liver. Approximately one-sixth of the NAFLD
Externí odkaz:
https://doaj.org/article/a5febd193c2f4d33a5582ec8dfb56cb9
Publikováno v:
Cell Reports Medicine, Vol 1, Iss 4, Pp 100057- (2020)
Summary: Experimental fibroblast growth factor 21 (FGF21) analogs can improve lipid profiles in patients with metabolic diseases. However, their effects on markers of insulin sensitivity appear to be minimal, potentially because of insufficient expos
Externí odkaz:
https://doaj.org/article/ff70adc410394e34a7243a26c6816dac
Autor:
Nathanael G Lintner, Kim F McClure, Donna Petersen, Allyn T Londregan, David W Piotrowski, Liuqing Wei, Jun Xiao, Michael Bolt, Paula M Loria, Bruce Maguire, Kieran F Geoghegan, Austin Huang, Tim Rolph, Spiros Liras, Jennifer A Doudna, Robert G Dullea, Jamie H D Cate
Publikováno v:
PLoS Biology, Vol 16, Iss 4, p e1002628 (2018)
[This corrects the article DOI: 10.1371/journal.pbio.2001882.].
Externí odkaz:
https://doaj.org/article/3cb85e619abd466a91199f6643f6fcd9
Autor:
Nathanael G Lintner, Kim F McClure, Donna Petersen, Allyn T Londregan, David W Piotrowski, Liuqing Wei, Jun Xiao, Michael Bolt, Paula M Loria, Bruce Maguire, Kieran F Geoghegan, Austin Huang, Tim Rolph, Spiros Liras, Jennifer A Doudna, Robert G Dullea, Jamie H D Cate
Publikováno v:
PLoS Biology, Vol 15, Iss 3, p e2001882 (2017)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in regulating the levels of plasma low-density lipoprotein cholesterol (LDL-C). Here, we demonstrate that the compound PF-06446846 inhibits translation of PCSK9 by inducing the ri
Externí odkaz:
https://doaj.org/article/c8c20b848f9a4b7e848edcb19074a5c8
Publikováno v:
British journal of pharmacology. 179(7)
Background and purpose Analogues of fibroblast growth factor 21 (FGF21) demonstrate diverse metabolic benefits in preclinical models of type 2 diabetes, dyslipidaemia, and non-alcoholic steatohepatitis (NASH), but clinical responses with different an
Autor:
Erik Tillman, Reshma Shringarpure, Guy Neff, Rashmee Patil, Peter Ruane, Bradley Freilich, Cynthia Behling, Erica Fong, Brittany de Temple, Kitty Yale, Stephen Harrison, Tim Rolph
Publikováno v:
Journal of Hepatology. 77:S719
Publikováno v:
Cell Reports Medicine, Vol 1, Iss 4, Pp 100057-(2020)
Cell Reports Medicine
Cell Reports Medicine
Summary Experimental fibroblast growth factor 21 (FGF21) analogs can improve lipid profiles in patients with metabolic diseases. However, their effects on markers of insulin sensitivity appear to be minimal, potentially because of insufficient exposu
Autor:
Matt Czech, Chris Brooks, Jaspreet Bhangu, Sanford Auerbach, Michael Kelley Erb, Farzad Mortazavi, Tim Rolph, Daniel R. Karlin, Nina Shaafi Kabiri, Kevin Thomas, Paolo Bonato
Publikováno v:
Chronobiology international. 37(5)
The continuous, longitudinal nature of accelerometry monitoring is well-suited to capturing the regular 24-hour oscillations in human activity across the day, the cumulative effect of our circadian rhythm and behavior. Disruption of the circadian rhy
Autor:
Paul DaSilva-Jardine, Jessica Ward, Katherine Cialdea, Matthew F. Calabrese, Marina Amaro, Harmeet Gandhok, Francis Rajamohan, Alan C. Opsahl, Mara Monetti, Kimberly O. Cameron, Tim Rolph, Eliza Bollinger, Benjamin S. Maciejewski, Ravi G. Kurumbail, Christopher T. Salatto, Timothy M. Coskran, David A. Tess, Aditi Jatkar, Nathan E. Genung, Emily Cokorinos, Allan R. Reyes, Morris J. Birnbaum, Germaine Boucher, John M. Kreeger, Andre Shavnya, David J. Edmonds, Russell A. Miller, Amit S. Kalgutkar
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 361:303-311
Diabetic nephropathy remains an area of high unmet medical need, with current therapies that slow down, but do not prevent, the progression of disease. A reduced phosphorylation state of adenosine monophosphate-activated protein kinase (AMPK) has bee
Publikováno v:
Journal of Hepatology. 73:S660-S661